Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Dose-escalation models for combination phase I trials in oncology

(2010) Paul Hamberg et al.   EUROPEAN JOURNAL OF CANCER

A new era: melanoma genetics and therapeutics

(2010) Justin M Ko et al.   JOURNAL OF PATHOLOGY

Melanoma: A model for testing new agents in combination therapies

(2010) Paolo A Ascierto et al.   Journal of Translational Medicine

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

(2010) Shivanni Kummar et al.   NATURE REVIEWS DRUG DISCOVERY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Therapy Reform

(2010) A. D. Levinson   SCIENCE

Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

(2009) B. Li et al.   CLINICAL CANCER RESEARCH

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE